$DVA

BERKSHIRE HATHAWAY INC sold $36.5M of DVA (indirect holdings)

BERKSHIRE HATHAWAY INC sold 182,980 indirectly-held shares of DAVITA INC. (DVA) at $199.55 ($36.51M total) on 2026-07-31.

Original reporting
SEC EDGAR · BERKSHIRE HATHAWAY INC
Published Aug 4, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVA
Neutral
medium confidence
Mentioned
$DVA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

Traders may monitor for follow-on filings (additional sales or changes in ownership) and for any concurrent DaVita-specific catalysts, but this single transaction alone is unlikely to drive a durable repricing.

02

Market read

A disclosed $36.5M open-market sale by a major 10% owner is a modest sentiment datapoint for DaVita, with limited direct fundamental implications.

03

What to watch

Indirect holdings and the lack of stated reason mean the sale could be tax, diversification, or rebalancing rather than a view on DaVita’s outlook.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-04, sale executed 2026-07-31

Background

The article is an SEC Form 4 insider transaction disclosure, where Berkshire Hathaway reports a sale of DaVita shares held indirectly as a 10% owner.

Company-level read

Ticker impact

$DVANeutralMedium confidence
Context

Berkshire Hathaway, as a 10% owner, filed a Form 4 showing an open-market sale of 182,980 DaVita shares for about $36.5M on 2026-07-31.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and should fade unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure with clear size and price, but it provides no rationale, no 10b5-1 plan, and no accompanying operational or guidance change for DaVita.

Market effects

Minimal. Large-holder sales in healthcare services typically do not reset sector fundamentals without additional company or regulatory catalysts.

None indicated.

None indicated.

Counterpoint

The absence of a pre-arranged 10b5-1 plan could be interpreted as less mechanical selling, but without context it is still not evidence of deteriorating fundamentals.

Key entities

  • Berkshire Hathaway Inc.

    Reported an open-market sale of DaVita shares via indirect holdings on 2026-07-31.

  • DaVita Inc.

    The company whose shares were sold, with holdings after the transaction reported in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DVAMedAI 8/10

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.